A new wave of GLP-1 drug shortages is hitting pharmacies nationwide as demand surges past supply capacity. An estimated 40 million Americans are now taking some form of GLP-1 medication for weight loss or diabetes management.
Why the Shortage Is Back
Novo Nordisk and Eli Lilly have ramped up production facilities, but demand continues to outpace manufacturing. The problem is compounded by new clinical data showing GLP-1 drugs reduce heart attack risk by 20%, leading more cardiologists to prescribe them.
What Patients Should Know
- Generic semaglutide expected by late 2027
- Compounding pharmacies filling the gap but face FDA scrutiny
- Insurance coverage expanding but still inconsistent
- New oral versions may ease injection supply pressure
The average monthly cost without insurance remains around $1,200, though manufacturer discount programs can bring it down to $500 for qualifying patients.
